Sarcoma News & Features
Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.
Mesenchymal chondrosarcoma, which often affects young adults, is among the deadliest cancers.
Adult patients with sarcoma experience significant symptom burden, which has a strong negative impact on health-related quality of life.
Data from a phase 2 trial supports continuation of trabectedin for patients with advanced soft-tissue sarcoma (STS) who have not progressed after six courses of treatment.
Image-guided radiotherapy can effectively treat soft tissue sarcomas in the extremities.
A diagnosis of soft-tissue sarcoma can leave many patients unsure of what to do next. This fact sheet provides more information about this type of cancer and lists sources of support.
- Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions
- Late-Stage Lung Cancer Often Overtreated
- Patients With Multiple Myeloma Vulnerable to Financial Toxicity Due to Costly Treatments
- New Treatment Option May Increase Metastatic Lung Cancer Survival
- New Approach Tackles Hormone Therapy Resistance in Breast Cancer
- Initial Safety Report Finds Acceptable Safety With Ibrutinib for Asymptomatic, High-Risk CLL
- Primary Care Physicians May Be Key to Meeting the Growing Demand for Cancer Care
- Half-Match Donors May be the Perfect Match In Transplantation for Blood Cancers
- Gay, Bisexual Men Report Higher Rates of Skin Cancer Than Heterosexual Men
- Fukushima Radiation May Be Increasing Pediatric Thyroid Cancer Rates
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|